Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 71fludarabine phosphate 63Busulfan 47Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Mycophenolic Acid 37Antilymphocyte Serum 37Filgrastim 32Cyclosporine 30Melphalan 29Whole-Body Irradiation 28Radiotherapy 28fludarabine 26Methotrexate 23Methylprednisolone 18Etoposide 18Cord Blood Stem Cell Transplantation 17Rituximab 13Alemtuzumab 13Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 10Sirolimus 9Thiotepa 8Cytarabine 8sargramostim 7Prednisone 7Epoetin Alfa 7Flow Cytometry 6thymoglobulin 5Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Glycopeptides × Plasma cell × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡